COVID-19 Progression in End-Stage Kidney Disease

Completed

Conditions studied: SARS-CoV-2 Infection (Asymptomatic), SARS-CoV-2 Infection (Symptomatic)

In brief

The purpose of this study is to collect genomic and clinical data among a cohort of hemodialysis patients and analyze the association between genetic markers and the development and severity of illness in response to SARS-CoV-2.

Key facts

Study ID

NCT04495907

Run by

Davita Clinical Research

People needed

412

Starts

2020-08-06

Expected to finish

2021-08-31

Last updated by the study team

2022-03-22

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Is 18 years or older at the time of consent
• Ability to provide informed consent.
• Is currently receiving hemodialysis treatment for end-stage kidney disease at a DaVita dialysis center.
• Enrollment in prior genomics study (Additional criteria for type B only)

Where it is running

• DCR Victorville — Victorville, California, United States
• DCR Connecticut — Bridgeport, Connecticut, United States
• DCR Twin Cities — Minneapolis, Minnesota, United States
• DCR Las Vegas — Las Vegas, Nevada, United States
• DCR Bronx — The Bronx, New York, United States
• DCR Canton — Canton, Ohio, United States
• DCR El Paso — El Paso, Texas, United States
• DCR Lewisville — Lewisville, Texas, United States
• DCR San Antonio — San Antonio, Texas, United States
• DCR Norfolk — Norfolk, Virginia, United States
• DCR Milwaukee — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.